Beclometasone Dipropionate HFA Aerosol for Lung Function Maintenance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhaled corticosteroid (ICS) treatments for asthma, such as fluticasone propionate and CFC-beclometasone, often fail to maintain lung function above 60% of baseline FEV1 in patients, leading to suboptimal asthma management.
Innovation Solution
An inhalable pharmaceutical solution aerosol comprising beclometasone dipropionate, ethanol, and a hydrofluorocarbon propellant (1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane) with a droplet size of 0.5-2.0 µm, administered via a pressurized metered-dose inhaler, which is free of surfactants to prevent chemical degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fluticasone propionate or CFC-beclometasone dipropionate is used for inhalable corticosteroid treatment, then anti-inflammatory effect is achieved, but lung function cannot be maintained above 60% of baseline FEV1 in patients with severe asthma
Solution Approach 1:
The patent changes the physical-chemical parameters of the corticosteroid formulation by using beclometasone dipropionate with specific solubility characteristics in HFA propellants, creating a solution that delivers consistent drug deposition and maintains lung function above 60% of baseline FEV1, resolving the inadequacy of previous ICS formulations
Solution Approach 2:
The patent creates a composite aerosol formulation combining beclometasone dipropionate with hydrofluorocarbon propellants (HFA 134a or HFA 227) and ethanol co-solvent, forming a stable solution that optimizes drug delivery and achieves reliable lung function maintenance in severe asthma patients
2Stability of the object's composition
If beclometasone dipropionate is dissolved in CFC propellant with ethanol, then solubility is achieved, but chemical degradation occurs due to surfactant presence
Solution Approach 1:
The patent removes surfactants from the formulation entirely, relying on the solubility properties of beclometasone dipropionate in the HFA propellant-ethanol solution system, thereby eliminating the source of chemical degradation while maintaining formulation stability
Solution Approach 2:
The patent uses hydrofluorocarbon propellants which provide an inert chemical environment that prevents degradation of the corticosteroid active ingredient, replacing the reactive CFC propellants and eliminating surfactant-related degradation pathways
3Productivity
If droplet size is reduced to improve lung deposition, then delivery efficiency increases, but formulation stability becomes more difficult to maintain
Solution Approach 1:
The patent optimizes the physical parameters of the aerosol formulation including droplet size distribution and propellant composition to achieve fine particle delivery (MMAD 1-3 µm) while maintaining formulation stability through the specific HFA propellant-ethanol-corticosteroid solution system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aerosol formulation effectively maintains lung function above 60% of baseline FEV1, reducing occurrences of lung function decline, providing improved asthma management compared to other ICS treatments.
Implementation Method 1
an inhalable pharmaceutical solution aerosol comprising beclometasone dipropionate, ethanol and a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, wherein the aerosol has a droplet size having a mass median aerodynamic diameter of 0.5-2.0 μm
Implementation Method 2
a pharmaceutical solution aerosol formulation comprising beclometasone dipropionate, a hydrofluorocarbon propellant selected from 1 ,1 ,1,2-tetrafluoroethane (norflurane or propellant 134a), 1 , 1 ,1,2,3,3,3-heptafluoropropane (propellant 227) and a mixture thereof, and ethanol (anhydrous) to solubilise the beclometasone dipropionate in the propellant
Data Source
Figure 1~4
AI summary
An inhalable pharmaceutical solution aerosol comprising beclometasone dipropionate, ethanol and a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, wherein the aerosol has a droplet size having a mass median aerodynamic diameter of 0.5-2.0 μm, for maintaining lung function above 60% of baseline FEV1, or reducing the occurrences of lung function falling below 60% of baseline FEV1.